Pfizer Beefs Up Its RSV Antiviral Portfolio With $525M ReViral Acquisition

Pfizer Inc PFE has agreed to acquire ReViral Ltd, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics for the respiratory syncytial virus (RSV).

• Pfizer will pay up to $525 million, including upfront and development milestones. 
• If successful, Pfizer believes annual revenue for these programs has the potential to reach or exceed $1.5 billion. 
• Related: Pfizer's RSV Vaccine Candidate Receives FDA Breakthrough Therapy Tag For Prevention of RSV In Older Adults.
• ReViral has a portfolio that includes sisunatovir, an orally administered inhibitor designed to block the fusion of the RSV virus to the host cell. 
• Sisunatovir significantly reduced viral load in a phase 2 RSV human challenge study in healthy adults and is currently in phase 2 clinical development in infants. 
• The development program for sisunatovir is expected to continue in both adult and pediatric populations.
• A second program is focused on the inhibition of RSV replication by targeting the viral N protein. The lead candidate in this program is currently in phase 1 clinical development.
• Price Action: PFE shares are up 2.63% at $54.26 during the market session on the last check Thursday.